Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2019-04-08 Report Publication Anno…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release dated April 8, 2019, announcing the 'Mise à disposition du Document de Référence 2018' (Making available of the 2018 Reference Document). It explicitly states that the 'Document de Référence 2018' has been filed with the AMF (Autorité des Marchés Financiers) and is available to the public. The text mentions that this Reference Document integrates the annual financial report, corporate governance report, and auditor reports for 2018. Since this document is an announcement *about* the publication of a major regulatory filing (the Reference Document, which contains the 10-K equivalent information), and it is short and directs the reader to where the actual document can be found, it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. If the text provided were the full Reference Document itself, it would likely be classified as 10-K or CGR/AR, but as an announcement of availability, RPA is the most accurate classification.
2019-04-08 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document text explicitly announces an 'Assemblée générale ordinaire' (Annual General Meeting) scheduled for April 26, 2019. It details the location, mentions the agenda and resolutions, and refers to the official notice published in the BALO (Bulletin des Annonces Légales Obligatoires). This content directly relates to the materials and announcements concerning the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R).
2019-04-05 French
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 1% confidence The document explicitly announces the details for an "Ordinary General Meeting on April 26, 2019." It provides the date, time, location, and mentions that the official notice, including the agenda and draft resolutions, was published in the official bulletin. This content directly relates to the preparation and announcement of a shareholder meeting, which aligns perfectly with the definition of AGM Information (AGM-R). Although it mentions the official notice publication, the primary focus is the meeting itself, making AGM-R more specific than a general Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2019-04-05 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is an announcement from Onxeo detailing that they will present data supporting their lead asset AsiDNA™ in five poster presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting. It provides details about the abstracts, sessions, dates, and scientific findings, but it is not the full financial report (10-K, IR), a formal earnings release (ER), or a transcript (CT). Since it is an announcement about scientific data being presented at a conference, it falls under general investor/corporate information related to R&D progress. Given the options, this type of scientific update, which is not a formal financial report or a specific management/governance filing, is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation slides themselves. However, as a press release announcing poster presentations, RNS is the most appropriate general category for non-standard corporate updates, although it strongly relates to investor information. Given the context of presenting scientific data, which is often shared with investors, and the lack of a specific 'Scientific Update' code, RNS serves as the best fit for this type of corporate communication detailing conference participation and abstract summaries.
2019-03-25 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2019, announcing that Onxeo will present new data on its drug candidate AsiDNA™ via five posters at the upcoming American Association for Cancer Research (AACR) annual meeting (March 29 - April 3, 2019). The text details the abstracts, presentation dates, and scientific findings. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing announcing results (like ER). It is an announcement detailing scientific data to be presented at an external industry conference. This type of communication, focusing on scientific data presentation and pipeline updates, is best classified as an Investor Presentation (IP) or a general announcement. Given the focus on presenting detailed scientific abstracts and data summaries intended for investors and the scientific community, 'Investor Presentation' (IP) is a strong fit, although it is structured as a press release. However, since the core content is the announcement of scientific data being presented at a conference, and it is not a formal, structured presentation document itself, it functions as a high-level update for investors about upcoming scientific disclosures. If the document were the actual slides, it would be IP. As a press release *about* presentations, it often falls under general Investor Relations communication. Since the content is highly specific scientific data dissemination, and it is not a standard earnings release or capital event, 'Investor Presentation' (IP) captures the intent of sharing detailed, forward-looking scientific/development information with the investment community, even if it's in press release format. Alternatively, 'Regulatory Filings' (RNS) is a fallback. Given the detailed scientific content being highlighted for investors, IP is the most specific fit among the options for non-financial/non-governance updates.
2019-03-25 French
Communicated under the obligation to provide permanent information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update." It contains detailed consolidated financial statements (income statement table), discusses revenues, operating expenses, net loss for the full year 2018, and provides a cash position as of December 31, 2018. This content strongly indicates a comprehensive annual financial report. Although it is an 'Earnings Release' style announcement summarizing the results, its depth, inclusion of the full income statement table, and explicit reference to the 'full-year 2018 financials' suggest it is the primary release of the annual results, which aligns best with the Annual Report (10-K) category, or potentially a very detailed Earnings Release (ER). Given the comprehensive nature and the explicit mention of the full-year results being approved by the Board, it functions as the primary annual financial disclosure. Since the text does not explicitly state it is the 10-K filing itself, but rather the report of the results, and it is a comprehensive annual summary, '10-K' is the most appropriate classification for a full-year financial report summary, even if it's a press release version. If it were significantly shorter and only highlighted key figures, ER would be better, but this document contains substantial financial detail. FY 2018
2019-03-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.